closed just below breakeven at 8,494.75. Both the Nasdaq and S&P 500 were up more than 1% at their session highs.
that Gilead Sciences' drug remdesivir did not improve patients' condition or reduce the coronavirus pathogen in their bloodstreamGilead took issue with the report, saying: "Because this study was terminated early due to low enrollment, it was underpowered to enable statistically meaningful conclusions. As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease.
"Any sort of treatment is key for people to getting people back out into the world," said Kim Forrest, founder of Bokeh Capital, on CNBC's " Earlier in the week, concerns over a lack of energy demand sent WTI's May contract — which expired Tuesday — into a negative price. Crude prices are also down sharply year to date even after their strong gains over the past two days.
Mixed results equals volatile market, stay tuned.
Corrupt
This market is manipulated. GILD was manipulated badly last week just to push stocks higher. There was no proof it works. People became rich in a day. It is not showing ttue face of economy, just bunch of hunches.
We are living the mother of manipulations ... the world will not give in to the hands of this sick current that leads this global conspiracy ... The actors are unmasked .....
This market is manipulated. GLED was manipulated badly last week just to push stocks higher. There was no proof it works. People became rich in a day. It is not showing ttue face of economy, just bunch of hunches.
Your corporate masters are pleased dimwit investors. Keep ignoring facts and the historic numbers that continue to come out. Infinite bull market!
Millions unemployed Profits falling Lying madman is POTUS Markets rising 🙄
Nigeria Nigeria Latest News, Nigeria Nigeria Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: AP - 🏆 728. / 51 Read more »
Source: Reuters - 🏆 2. / 97 Read more »
Source: CNBC - 🏆 12. / 72 Read more »